Letters, Testimony & Filings Testimony Before the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee Regarding Andexanet (Andexxa) November 21, 2024
Outrage of the Month: The Continuing Influence of Industry Payments to U.S. Physicians November 1, 2024
Letters, Testimony & Filings Testimony Before the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee Regarding Sotagliflozin October 31, 2024
Letters, Testimony & Filings Testimony before the FDA’s Pharmacy Compounding Advisory Committee about Hydroxyprogesterone Caproate October 29, 2024
Letters, Testimony & Filings Outrage of the Month: Expanded FDA Approval of a Gene Therapy for Muscular Dystrophy October 1, 2024
Press Releases Medicare Could Save $14 Billion with Access to Ozempic and Wegovy Generics September 24, 2024